Table 1

Patient characteristics and outcomes, considering all patients and 4 subgroups as recognised by the HPB MDT

All patientsGroup 1
BCLC-B too large for TACE alone
Group 2
BCLC-B progression post TACE
Group 3
BCLC-C sorafenib eligible
Group 4
BCLC-C sorafenib unsuitable
Patient number51217167
age—median (range)72 (39–84)72 (51–84)76 (62–81)68 (50–81)72 (39–84)
Sex M/F41/1015/66/116/04/3
Aetiology—no CLD83023
 ARLD93330
 NAFLD1910252
 HCV93051
 Other62211
Cirrhosis N/Y20/3111/101/65/113/4
Child-Pugh A51217167
ECOG PST 0/1/221/22/814/7/03/4/04/8/40/3/4
Tumour number 1/>130/2114/72/510/64/3
Size—median, cm
(range)
8.5
(3.3–19.1)
9.7
(5.3–19.1)
5.9
(3.3–11.0)
8.8
(3.7–13.0)
8.3
(3.8–17.0)
Total activity—median GBq (range)3.2
(1.04–10.77)
3.93
(1.49–10.77)
2.32
(1.04–3.20)
3.20
(1.61–6.67)
2.8
(1.26–6.53)
Branch PVT N/Y39/1221/07/06/105/2
Unilobar Y/N39/1216/55/213/35/2
Prior therapy Y/N17/342/197/05/113/4
Next therapies
 Resection55000
 Active monitoring33000
 Further SIRT10010
 Medical 1 L81250
 Medical 1l+2 L73031
 Supportive care279576
mRECIST PR/SD/PD (3 months)25/11/1412/6/22/0/57/5/44/0/3
Median survival (months)
All—median20.17Ongoing14.820.24.2
Resection n=5OngoingAll alive
Non-resected15.521.7
First-line SIRT21.67Ongoing27.43.7
Second-line SIRT10.9342.114.810.77.3
Unilobar19.87Ongoing11.427.44.2
Bilobar10.9320.214.88.83.2
+PVT10.710.72.7
  • ARLD, alcohol related liver disease; BCLC, Barcelona clinic liver cancer; CLD, chronic liver disease; ECOG PST, European Co-operative Oncology Group Performance Status; F, female; GBq, gigabecquerel; HCV, hepatitis C virus; 1L, first line; 2L, second line; M, male; mRECIST, modified response evaluation criteria in solid tumours; N, no; NAFLD, non-alcoholic fatty liver disease; PVT, portal vein thrombus; SIRT, selective internal radiation therapy; TACE, transarterial chemoembolisation; Y, yes.